# The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis

> **NCT02211690** · PHASE4 · COMPLETED · sponsor: **Andrew Carr** · enrollment: 100 (actual)

## Conditions studied

- Human Immunodeficiency Virus

## Interventions

- **DRUG:** dolutegravir 50 mg (one tablet daily)
- **DRUG:** emtricitabine-tenofovir 300/200 mg (one tablet daily)

## Key facts

- **NCT ID:** NCT02211690
- **Lead sponsor:** Andrew Carr
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-11
- **Final completion:** 2016-02
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2016-05-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02211690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02211690, "The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02211690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*